ChemoCentryx

ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan

... treatment of inflammatory diseases." About chemocentryx ChemoCentryx, Inc. is a clinical-stage biophar...tary drug discovery and drug development platform, chemocentryx has internally generated multiple clinical and pre...nflammatory diseases such as rheumatoid arthritis. chemocentryx also has several programs in preclinical developme...

ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors

...tary drug discovery and drug development platform, chemocentryx has internally generated several clinical and prec..., please refer to http://www.chemocentryx.com . chemocentryx believes that certain statements in this release m...tatements include, but are not limited to (i) that chemocentryx anticipates incurring significant losses for the f...

ChemoCentryx in Medical Technology

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... unparalleled clinical development progress by the chemocentryx team. This is true not only for our CCR9 program, ...ct T cells are thought to play an important role. chemocentryx has completed five Phase I clinical trials and one...ents have few options beyond surgery. About chemocentryx ChemoCentryx, Inc., is a clinical-stage biophar...

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

... ChemoCentryx's Second-Generation CCR9 Program chemocentryx is also advancing a second-generation, orally-acti...ctant receptors. Under the terms of the agreement, chemocentryx is responsible for advancing product candidates th...clinical and discovery programs, clearly positions chemocentryx as an industry leader in chemokine-based therapeut...

ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354

...ith the dosing of the first patient in this trial, chemocentryx will be entitled to receive a $10 million mileston... as it emerges from the clinical trial program." chemocentryx and GSK's Center of Excellence for External Drug D...atory disorders. Under the terms of the agreement, chemocentryx is responsible for the discovery and development o...

ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007 Conference

...ilar in both the placebo and Traficet-EN groups. chemocentryx is currently evaluating Traficet-EN in a large mul...nts have few or no options beyond surgery. About chemocentryx ChemoCentryx, Inc. is a clinical-stage biopharma...tary drug discovery and drug development platform, chemocentryx has internally generated several clinical and prec...

ChemoCentryx in Biological Technology

ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week

... (CDAI) score of at least 70 points. About chemocentryx ChemoCentryx, Inc., is a clinical-stage biopha...tary drug discovery and drug development platform, chemocentryx has internally generated multiple clinical and pre...flammatory diseases such as rheumatoid arthritis. chemocentryx also has several programs in preclinical developme...

ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist

...Chief Executive Officer. "I am gratified that the chemocentryx team has again demonstrated the broad capability o... between the C5a receptor and chemokine receptors, chemocentryx researchers successfully applied the company's pro...ptor targets covered under a 2006 alliance between chemocentryx and GlaxoSmithKline's Center of Excellence for Ext...

ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development

... "With the advancement of CCX025 into the clinic, chemocentryx can pursue a greater breadth of diseases associate...ptor targets covered under a 2006 alliance between chemocentryx and GlaxoSmithKline's Center of Excellence for Ext...tary drug discovery and drug development platform, chemocentryx has internally generated multiple clinical and pre...

ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth

...was discovered and characterized by ChemoCentryx. chemocentryx scientists, joined by researchers from the Univers...coded by a gene of previously unknown function) at chemocentryx through the company's proprietary EnabaLink Drug D...th high affinity to a specific chemokine receptor. chemocentryx has leveraged its EnabaLink Drug Discovery engine ...